Novartis "can never be done" when it comes to major acquisitions in its sector as it always needs to look for the next "great ...

Among tariffs, pricing policies and ongoing negotiations, pharma leaders can’t help but address their dealings with the Trump ...

Spot shows folks running as a symbol of how the health-challenged can chase their dreams because of Sanofi meds.

Texas AG Ken Paxton accuses J&J and Kenvue of hiding Tylenol's autism risks for pregnant women in new lawsuit.

Merck announced that sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago. The pharma giant also narrowed its full-year profit outlook ...

Decision is a setback for Dr. Reddy’s Laboratories, which was poised to be one of the first generic competitors to Ozempic ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing d | Dianthus and Boehringer Ingelheim ...

AstraZeneca (LSE:AZN) has delivered returns of 12% over the past month and 16% in the past 3 months, catching the attention ...

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

Dr Reddy's CEO Erez Israeli says the pivot is already visible - India and Europe growth is now driven by innovation, consumer ...